Drug Patent Watch
JUNE 7, 2022
This article was originally published by Guy Shtar, Louise Azulay, Omer Nizri, Lior Rokach & Bracha Shapira in Scientific Data volume 9, Article number: 263 under a Creative Commons Attribution…. The post CDCDB: A large and continuously updated drug combination database appeared first on DrugPatentWatch - Make Better Decisions.
Olympian Clinical Research
JUNE 10, 2022
Atopic dermatitis is a form of eczema and is the most common chronic inflammatory skin disease. While this condition is often seen in children, around 16.5 million Americans suffer from this itchy skin condition. Although there is no cure for this condition, with the proper knowledge, treatments, and lifestyle changes, those with eczema may manage their symptoms and lead happy, healthy lives.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
JUNE 6, 2022
Time for an update to the Drug Channels Institute (DCI) annual analysis of pharmacist salaries and employment. The retail pharmacy shakeout affected 2021 pharmacist employment. We found that retail pharmacies and drugstores employed fewer pharmacists, while hospitals and outpatient centers continued to add positions. As a result, the share of pharmacists who work in non-retail practice settings reached a new high.
Advarra
JUNE 9, 2022
Optimizing clinical trial access for potential patients is a critical goal for researchers and sponsors. How can we make clinical research more accessible to anyone who wishes to participate? Decentralized clinical trials (DCTs) can meet that need, but they come with some challenges. The concept of DCTs brings the trial activities to non-centralized places, closer to participants, so they have better access to the interventions and measures involved in conducting a trial.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Patent Watch
JUNE 5, 2022
This chart shows the drugs with the most patents in Norway. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Norway? appeared first on DrugPatentWatch - Make Better Decisions.
Olympian Clinical Research
JUNE 8, 2022
Do you or someone that you care about suffer from migraines? Are you wondering what options you may have? Consider the PRECLUDE study – a clinical research study for patients with episodic migraines. About Migraines. Migraines are headaches of moderate to severe intensity and may also include symptoms of nausea, vomiting, and sensitivity to light or sound.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Crown Bioscience
JUNE 7, 2022
In this post, we explore multi-drug combination screening studies, including major design and analysis strategies, and how novel high content technologies are being used to identify promising multi-drug combination regimens more efficiently.
Drug Patent Watch
JUNE 10, 2022
This chart shows the patent expirations for solution dosed drugs over the next decade. The term of drug patents varies. The basic term for a patent is 20 years from…. The post Solution dosed drug patent expirations by year appeared first on DrugPatentWatch - Make Better Decisions.
Advarra
JUNE 6, 2022
Advarra expert Steffen Engel answers questions from the recent webinar, Stepwise Implementation of a Clinical Quality Management System. Q: How do you promote a quality culture when senior management has a lack of knowledge of quality management systems (QMS) and is more interested in deliverables rather than quality? . A: That is a tough one. First, congratulations on realizing such a mindset may exist.
The Pharma Data
JUNE 7, 2022
New Indication for Amgen’s Fifth FDA-approved Biosimilar. Now Approved to Treat All Available Rituxan ® Indications. Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan ® , in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
The Anticancer Fund
JUNE 7, 2022
10 June 2022 Language EN Drug repurposing is a strategy for identifying new uses for approved drugs, outside the scope of the original indication. It is one of the focus areas of the Anticancer Fund. Below, we have listed recent findings about the repurposing of generic drugs in oncology. Our intention is to help bring these findings to the attention of the broader cancer research community.
Drug Patent Watch
JUNE 9, 2022
This chart shows the patent expirations for solution dosed drugs over the next decade. The term of drug patents varies. The basic term for a patent is 20 years from…. The post Solution dosed drug patent expirations by year appeared first on DrugPatentWatch - Make Better Decisions.
Broad Institute
JUNE 7, 2022
Access denied By admin June 7, 2022 Breadcrumb Home Access denied Access denied 403
The Pharma Data
JUNE 6, 2022
Safety results suggest a manageable safety profile for elranatamab in this patient population with advanced multiple myeloma With a median follow up of 3.71 months, initial efficacy results showed the objective response rate for elranatamab was 60.6%. Pfizer Inc. (NYSE: PFE) today announced new data from a planned interim analysis of the Phase 2 MagnetisMM-3 registration-enabling trial of elranatamab in people with relapsed/refractory multiple myeloma (RRMM) whose disease is refractory to at lea
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Pharma Manufacturing
JUNE 9, 2022
Fulfilling the promise of CGT will require a carefully cultured talent ecosystem
Drug Patent Watch
JUNE 9, 2022
Annual Drug Patent Expirations for ZYRTEC-D+12+HOUR Zyrtec-d 12 Hour is a drug marketed by J And J Consumer Inc and is included in one NDA. It is available from one…. The post New patent expiration for J And drug ZYRTEC-D 12 HOUR appeared first on DrugPatentWatch - Make Better Decisions.
Drug & Device Law
JUNE 6, 2022
Confident prescribing physicians and implanting surgeons are the best “learned” intermediaries. They’re experienced at what they do and aren’t intimidated by plaintiffs’ counsel and their threats of malpractice claims if they don’t testify the way plaintiffs want them to. Confident learned intermediaries stand by their medical decisions. Thus a confident learned intermediary’s testimony will defeat causation as a matter of law by stating that, notwithstanding a poor result, the treatment prov
The Pharma Data
JUNE 7, 2022
80% of lebrikizumab responders maintained improvements in skin clearance and disease severity at 52 weeks; lasting improvements in itch were also observed. Data supported both once every two week and once every four week maintenance dosing, with consistent and durable responses. Eli Lilly and Company (NYSE: LLY) today announced topline results from one-year analyses of the efficacy and safety of lebrikizumab, the company’s investigational IL-13 inhibitor for the treatment of patients with
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Patent Watch
JUNE 9, 2022
Annual Drug Patent Expirations for ALTRENO Altreno is a drug marketed by Dow Pharm and is included in one NDA. It is available from one supplier. There is one patent…. The post New patent for Dow Pharm drug ALTRENO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 9, 2022
Annual Drug Patent Expirations for IMVEXXY Imvexxy is a drug marketed by Therapeuticsmd Inc and is included in one NDA. It is available from one supplier. There are eighteen patents…. The post New patent for Therapeuticsmd Inc drug IMVEXXY appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 9, 2022
Annual Drug Patent Expirations for SLYND Slynd is a drug marketed by Exeltis Usa Inc and is included in one NDA. It is available from one supplier. There are eight…. The post New patent for Exeltis Usa drug SLYND appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 8, 2022
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Norway. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Norway? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 8, 2022
Annual Drug Patent Expirations for EPIDIOLEX Epidiolex is a drug marketed by Gw Res Ltd and is included in one NDA. It is available from one supplier. There are twenty-one…. The post New patent for Gw Res drug EPIDIOLEX appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 8, 2022
Annual Drug Patent Expirations for FYCOMPA Fycompa is a drug marketed by Eisai Inc and is included in two NDAs. It is available from one supplier. There are two patents…. The post New patent for Eisai Inc drug FYCOMPA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 8, 2022
Annual Drug Patent Expirations for TRULANCE Trulance is a drug marketed by Salix and is included in one NDA. It is available from two suppliers. There are nine patents protecting…. The post New patent expiration for SALIX drug TRULANCE appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 7, 2022
This chart shows the pharmaceutical companies with the most patents in Japan. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Japan? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 7, 2022
Annual Drug Patent Expirations for ESKATA Eskata is a drug marketed by Aclaris and is included in one NDA. There are six patents protecting this drug. This drug has twenty-nine…. The post New patent expiration for Aclaris drug ESKATA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 7, 2022
Annual Drug Patent Expirations for FYCOMPA Fycompa is a drug marketed by Eisai Inc and is included in two NDAs. It is available from one supplier. There are two patents…. The post New patent expiration for Eisai Inc drug FYCOMPA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 7, 2022
Annual Drug Patent Expirations for COPIKTRA Copiktra is a drug marketed by Secura and is included in one NDA. There are four patents protecting this drug. This drug has one…. The post New patent for Secura drug COPIKTRA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 7, 2022
Annual Drug Patent Expirations for ZIMHI Zimhi is a drug marketed by Adamis Pharms Corp and is included in one NDA. The generic ingredient in ZIMHI is naloxone hydrochloride. Additional…. The post New patent for Adamis Pharms drug ZIMHI appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 4, 2022
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Italy. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Italy? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 7, 2022
TRULANCE (plecanatide) Salix Patent: 7,799,897 Expiration: Jun 9, 2022 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit…. The post Drug Patent Expirations for the Week of June 5, 2022 appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
JUNE 7, 2022
AL01811 is a preclinical selective GBA2 inhibitor with first-in-class potential as an oral disease modifying treatment for Parkinson’s Disease Alectos to receive a $15 million upfront payment and is eligible to receive potential future development and commercial milestone payments. Biogen Inc. (Nasdaq: BIIB) — Biogen and Alectos Therapeutics have entered into a license and collaboration agreement to develop and commercialize a novel preclinical selective GBA2 inhibitor, AL01811, which h
Expert insights. Personalized for you.
101 
Let's personalize your content